Historical Archive

Farmindustria: “We need a Pact. Generic rules distort the market. Stop”

The drug manufacturers don't even like the new Senate amendment on active ingredient prescriptions. “But ours is not a war on the generic. It is contrary to rules that actually favor those who do not invest in research and can afford discounts to pharmacists that are impossible for us”. We need a new three-year pact.

04 DEC “The amendment approved by the Senate Industry Commission on the prescription of generics does not change anything. We remain strongly opposed to a law that has in fact distorted the market by favoring not the generic but the companies that produce it, in an unacceptable way". It may have been a coincidence but the press briefing promoted by the top management of Farmindustria this morning to talk about innovation and enhancement of the brand, in the end focused once again on the controversy between branded industries and non-branded companies.

The reason for the dispute is thus once again the rule included in the spending review which provides for the obligation to indicate the active ingredient in the recipe. And the fact that the doctor is in any case given the possibility of also indicating the name of the branded medicinal product is not enough for Farmindustria.
“The rule, and the amendment by the Senate does not change anything – they say in Farmindustria – has created a real distortion in competition by offering companies that only produce generics an extra card to spend with pharmacies, offering purchase prices to distribution that we we will never be able to afford it because we have overhead costs much higher than them”.

"Making the pharmacist the last decision-maker on which equivalent product to offer to the citizen shifts all the commercial balances in favor of generic manufacturers", some industrialists tell us at the conclusion of the briefing. "And so - underlines Lucia Aleotti of Menarini who confirmed that as a result of this situation, 1,000 jobs in its factories are at risk – it happens that our patent-expired products, despite being sold at the reference price, are not 'chosen' by the pharmacist because

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco